Jul.14.2023
Management / Finance
Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Remuneration and Performance-linked Restricted Stock Remuneration
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO, Gyo Sagara; the “Company”) announced that the payment procedures were completed on July 14, 2023 as follows for disposal of treasury shares as tenure-based restricted stock remuneration and performance-linked restricted stock remuneration resolved at the Board of Directors meeting held on June 22, 2023. For more details, please refer to “Announcement on Disposal of Treasury Shares as Tenure-based Restricted Stock-based Remuneration and Performance-linked Restricted Stock-based Remuneration” dated June 22, 2023.
Overview of Disposal of Treasury Shares
1. Disposal as tenure-based restricted stock remuneration
| (1) | Disposal date | July 14, 2023 |
|---|---|---|
| (2) | Class and number of disposed shares | 15,300 shares of common stock of the Company |
| (3) | Disposal price | ¥2,767 per share |
| (4) | Total value of disposed share | ¥42,335,100 |
| (5) | Allottees and number thereof; number of disposed shares | Board of Directors of the Company (excluding Outside Directors): 4 persons / 15,300 shares |
2. Disposal as performance-linked restricted stock remuneration
| (1) | Disposal date | July 14, 2023 |
|---|---|---|
| (2) | Class and number of disposed shares | 30,900 shares of common stock of the Company |
| (3) | Disposal price | ¥2,767 per share |
| (4) | Total value of disposed share | ¥85,500,300 |
| (5) | Allottees and number thereof; number of disposed shares | Board of Directors of the Company (excluding Outside Directors): 4 persons / 20,100 shares Corporate Officers who are not the Board of Directors of the Company: 7 persons / 10,800 shares |